@gr-research.bsky.social
Pioneering oncology research. Bridging fundamental, translational, and clinical research to advance precision medicine. 👩🔬👨🔬 🔗 www.gustaveroussy.fr
🔹 Tarek Ben Ahmed presenting in the Poster Session on Prevention, Risk Reduction, and Genetics: One-year impact of a large-scale pilot multimodal personalized early #cancer detection and prevention program for individuals at high risk of cancer.
@ascocancer.bsky.social #ASCO25 #ASCO
🔹 Gustave Roussy at #ASCO25 🔹
Ines Vaz Luis at @ascocancer.bsky.social on eHealth in breast #cancer: bridging the gap in survivorship with decision-support tools, care coordination, self-management, and digital supportive care.
#BreastCancer #Survivorship #eHealth
🔹 Gustave Roussy at #ASCO25 🔹
Dr. Pablo Berlanga, paediatric oncologist at @gustaveroussy.fr, presents an innovative combination being tested as a first-line treatment for late diagnosis of Ewing's sarcoma at @ascocancer.bsky.social.
Press release ⤵
#ASCO
🔹 Gustave Roussy at #ASCO25 🔹
Dr Pablo Berlanga, onco-pédiatre à @gustaveroussy.fr, présente une combinaison innovante testée en première ligne dans les sarcomes d'Ewing diagnostiqués tardivement à l'#ASCO. ⤵
@ascocancer.bsky.social
🔹 Gustave Rouss at ASCO 2025 🔹
Prof. Laurence Zitvogel presents microbiome session at #ASCO.
@ascocancer.bsky.social
🔹 Gustave Roussy at #ASCO25 🔹
Barbara Pistilli discusses the positioning of Dato-DXd in the rapidly evolving landscape of ER-positive, HER2-low breast #cancer.
@ascocancer.bsky.social
🔹 Gustave Roussy à l'#ASCO25 🔹
Dr Antoine Hollebecque, oncologue à @gustaveroussy.fr, présente une nouvelle association de traitements pour les patients avec un cancer colorectal en échec thérapeutique à l'@ascocancer.bsky.social. ⤵
🔹 Gustave Roussy at #ASCO25. 🔹
The Institute's experts have arrived on site. Follow them throughout the weekend.
@ascocancer.bsky.social
🚀 #ASCO25 is on!
Keep up to date with news from @gustaveroussy.fr's doctors and researchers on social networks throughout the weekend. @ascocancer.bsky.social
New data in pancreatic #cancer!
The NEOPAN Phase III trial led by Prof. Michel Ducreux (@gustaveroussy.fr) shows FOLFIRINOX improves PFS vs gemcitabine in LAPC, with similar OS and QoL.
👉 doi.org/10.1200/JCO-...
#PancreaticCancer #OncoResearch #FOLFIRINOX
🎤 With Quentin Blampey, PhD – expert in spatial data science.
⏳ Don’t miss this opportunity to engage live and ask your questions!
👉 Register here:
prism.center/meeting/webi...
#SpatialOmics #Bioinformatics #SpatialTranscriptomics
Novae: a graph-based foundation model trained on nearly 30 M cells across 18 tissue types. Novae learns spatially-aware representations of cells to infer spatial domains, correct batch effects, and many other downstream tasks such as spatial gene/pathway analysis and domain trajectory inference.
⬇
Sopa: a memory-efficient, technology-invariant pipeline for spatial omics at single-cell resolution. Built on the SpatialData framework, Sopa is a toolkit for segmentation, aggregation, annotation, and geometric analysis across technologies.
⬇
🚨Few days left!
Join us this Friday, May 16 at 13:30 (Paris time) for a deep dive into computational methods for spatial omics analyses.
🔍 Discover how Sopa and Novae, two open-source powerfool tools for spatial transcriptomics research.
⬇
Researchers from the Crick, @ucl.ac.uk, @gr-research.bsky.social and @mskcancercenter.bsky.social have discovered that certain age-related genetic changes in the blood are associated with worse outcomes for cancer patients.
www.crick.ac.uk/news/2025-04...
📢 Excited to launch Signadori Bio with Sofinnova Partners!
Born from @gustaveroussy.fr research, this new biotech develops breakthrough cell therapies for #cancer. ⤵
#CellTherapy #CancerResearch #Biotech #OncologyInnovation #TranslationalResearch #GustaveRoussy #SofinnovaPartners #SignadoriBio
📸 Photo : © @ahmsab_MD on X
03.04.2025 13:21 — 👍 0 🔁 0 💬 0 📌 0
📰 New ERN-EuroBloodNet guidelines for adult Burkitt lymphoma now published in The Lancet Haematology. First EU-wide recommendations to harmonise diagnosis, risk-adapted treatment & prognosis.
🔗 doi.org/10.1016/S235...
#Lymphoma #Haematology
📢 New publication from @gustaveroussy.fr researchers & collaborators in Nature Cancer further supports the tumor-agnostic indication of pembrolizumab ! 📢
Read the study: doi.org/10.1038/s430...
Congrats to Thomas Mercher @gustaveroussy.fr, Erika Brunet @institutimagine.bsky.social and all involved in this beautiful study just out in Blood ⤵️
24.03.2025 14:54 — 👍 2 🔁 2 💬 0 📌 0NEW PUBLICATION!
Researchers from the @r4knetwork.bsky.social just revealed the progressive chromatin rewiring induced by the ETO2::GLIS2 fusion in the onset of pediatric leukemia.
A collaboration between @gustaveroussy.fr, @institutimagine.bsky.social, & many more.
doi.org/10.1182/bloo...
📣 We are excited to announce the first scientific day on liquid biopsy, organized by @gustaveroussy.fr and the IHU PRISM, taking place on June 11, 2025, in Paris! 🧬🔬
🔗 More information & registration:
📰 Low-dose gut radiation enhances immunotherapy.
New #research shows it boosts PD-L1 blockade, triggering a stronger systemic anti-tumor immune response. The gut microbiome plays a key role—this could be a game-changer for #cancer treatment.
#Immunotherapy #Oncology #PDL1
📰 Des chercheurs parviennent à reproduire une leucémie pédiatrique à partir de cellules humaines non-cancéreuses.
Communiqué de presse ⤵
📰 “De-escalation in Lung Cancer Treatment: Are We Ready?”
A new review in JCO explores de-escalation strategies for ICBs in NSCLC—reducing dose, duration, or frequency—to cut toxicity, costs, and improve global access without compromising efficacy.
🔗 ascopubs.org/doi/full/10....
📰 Gustave Roussy Authorised to Conduct Phase I Clinical Trials in Nuclear Medicine.
🎯 The Institute can now evaluate innovative radioligands administered for the first time or at an early stage in humans.
More informations 👇
🎯 IFODS 2025, le rendez-vous de l’oncologie française !
⤵⤵⤵
ifods.com
Congrès IFODS 2025 🚀
📅 Le 12/06/2025, lors du Congrès National d’Oncologie - IFODS, nous vous donnons rendez-vous pour une session Présidentielle : IFODS - Gustave Roussy », qui se déroulera sous la présidence de Fabrice Barlesi, Francoise Mornex et Jean-Philippe SPANO. ⤵
📰 Le Dr Elie Rassy, oncologue médical au sein du comité de pathologie mammaire de Gustave Roussy et co-investigateur d’ETNA, revient en cinq questions sur cet essai clinique.
⤵⤵⤵
🚀 Join us at the inaugural AI in Oncology 2025 Conference ! 🚀
📅 June 17-18, 2025
📍 Paris, France
🌍 Bringing together top researchers, clinicians, and industry leaders
🔗 Register now and be part of the conversation: www.aiinoncology.com
